CuraGen Advances CR011-vcMMAE Into Phase II

CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, announced that it has advanced CR011-vcMMAE, an antibody-drug conjugate (ADC), into Phase II for the treatment of patients with unresectable Stage III and Stage IV melanoma.

More: continued here

Filed under: Cancer on April 11th, 2008